⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1331223 | 1.00 | — | — | |
| SCHEMBL22905077 | 1.00 | — | — | |
| SCHEMBL879 | 1.00 | — | — | |
| Water SCHEMBL23042868 | 0.98 | LMNA (0.96) | — | |
| Water SCHEMBL23042869 | 0.98 | LMNA (0.96) | — | |
| SCHEMBL28787742 | 0.87 | LMNA (0.76) | — | |
| Imidazole SCHEMBL28835236 | 0.79 | LMNA (0.63) | — | |
| SCHEMBL6555571 | 0.76 | — | — | |
| SCHEMBL15856528 | 0.76 | — | — | |
| SCHEMBL438928 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 10637 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747627-A1 | METHODS AND SYSTEMS FOR PREDICTIVE CLASSIFICATION BY MASS SPECTROMETRY AND TRAINED LARGE SPECTRAL MODELS | Matterworks Inc (US) | 2026-05-27 | — | — | EP | claimed |
| WO-2026088246-A1 | METHOD FOR PRODUCING LOW-MOLECULAR-WEIGHT COMPOUND | ＮＴＴ株式会社 | 2026-04-30 | — | — | WO | claimed |
| EP-4296365-B1 | PROCESSES FOR CONVERSION OF BIOLOGICALLY DERIVED MEVALONIC ACID | VISOLIS INC (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260092023-A1 | PROCESS SYNTHESIZING SUSTAINABLE AVIATION FUEL COMPOSITIONS | VISOLIS INC (US) | 2026-04-02 | — | — | US | claimed |
| US-20260092130-A1 | PROCESS FOR SYNTHESIZING POLYMER COMPOSITIONS FROM STARTING MATERIALS COMPRISING A DOUBLE BOND | VISOLIS INC (US) | 2026-04-02 | — | — | US | claimed |
| EP-4706822-A2 | METHODS FOR RECOVERING ORGANIC ACIDS OR SALTS OR LACTONES THEREOF FROM AQUEOUS SOLUTIONS USING WATER SOLVENT CRYSTALLIZATION AND COMPOSITIONS THEREOF | Danisco US Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-20260028539-A1 | COMPOSITIONS FOR PRODUCTION OF OLEFINS, TERPENES, AROMATICS AND CYCLOALIPHATICS AND METHODS THEREFOR, AND PRODUCTS THEREFROM | VISOLIS INC (US) | 2026-01-29 | — | — | US | claimed |
| US-20260028433-A1 | PROCESS FOR SYNTHESIZING TACKIFYING COMPOSITIONS FROM STARTING MATERIALS COMPRISING A DOUBLE BOND | VISOLIS INC (US) | 2026-01-29 | — | — | US | claimed |
| US-12503421-B2 | Methods for recovering organic acids or salts or lactones thereof from aqueous solutions using water solvent crystallization and compositions thereof | DANISCO US INC. (US) | 2025-12-23 | — | — | US | claimed |
| EP-4357386-B1 | POLY(3-HYDROXYPROPIONIC ACID) BLOCK COPOLYMER, MANUFACTURING METHOD THEREOF AND PRODUCTS CONTAINING THE SAME | LG CHEMICAL LTD (KR) | 2025-10-29 | — | — | EP | claimed |
| EP-0461548-A2 | Method for preventing a second heart attack employing and HMG CoA reductase inhibitor | E.R. SQUIBB & SONS, INC. (US) | 1991-12-18 | — | — | EP | claimed |
| EP-0457514-A1 | Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor | E.R. SQUIBB & SONS, INC. (US) | 1991-11-21 | — | — | EP | claimed |
| EP-0436562-A1 | PROCESS FOR -i(IN VIVO) PRODUCTION OF ASTAXANTHIN AND -i(PHAFFIA RHODOZYMA) YEAST OF ENHANCED ASTAXANTHIN CONTENT. | IGENE BIOTECHNOLOGY INC (US) | 1991-07-17 | — | — | EP | claimed |
| WO-1991002060-A1 | PROCESSES FOR IN VIVO PRODUCTION OF ASTAXANTHIN AND PHAFFIA RHODOZYMA YEAST OF ENHANCED ASTAXANTHIN CONTENT | IGENE BIOTECHNOLOGY, INC. (US) | 1991-02-21 | — | — | WO | claimed |
| EP-0401705-A2 | Use of an HMG CoA reductase inhibitor and/or a squalene synthetase inhibitor for treating peripheral atherosclerotic disease | E.R. Squibb & Sons, Inc. (US) | 1990-12-12 | — | — | EP | claimed |
| EP-0373507-A1 | Combination of an HMG CoA reductase inhibitor and other type of serum cholesterol reducing agent and method for lowering serum cholesterol using such combination | E.R. SQUIBB & SONS, INC. (US) | 1990-06-20 | — | — | EP | claimed |
| WO-1990001552-A1 | PROCESS FOR IN VIVO PRODUCTION OF ASTAXANTHIN AND PHAFFIA RHODOZYMA YEAST OF ENHANCED ASTAXANTHIN CONTENT | IGENE BIOTECHNOLOGY, INC. (US) | 1990-02-22 | — | — | WO | claimed |
| EP-0170933-B1 | GAMMA-AMINOBUTYRIC ACID DERIVATIVES, PROCESS FOR PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | KURARAY CO., LTD. (JP) | 1988-08-31 | — | — | EP | claimed |
| EP-0060565-B1 | FULLY SYNTHETIC CELL CULTURE MEDIUM | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1986-06-25 | — | — | EP | claimed |
| EP-0060565-A2 | Fully synthetic cell culture medium | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1982-09-22 | — | — | EP | claimed |